跳至主要内容
临床试验/ACTRN12621001442897
ACTRN12621001442897已完成未知

Randomised Controlled Trial of a Standard Cognitive Behavioural Treatment versus Augmented Cognitive Behavioural Treatment on PTSD and Depression in Emergency Service Personnel

SW Sydney0 个研究点目标入组 100 人开始时间: 2021年10月25日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Meet criteria for PTSD as defined by DSM-5
  • Aged at least 18 years
  • Current or former member of Emergency Service Personnel
  • Sufficient English proficiency

排除标准

  • Current psychosis
  • Imminent suicidal risk
  • Current substance dependence

研究者

发起方
SW Sydney

相似试验

进行中(未招募)
1 期
A phase 3 study of parsaclisib plus ruxolitinib in patients with myelofibrosismyelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2020-003415-98-HUIncyte Corporation212
进行中(未招募)
1 期
An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Heterozygous Familial Hypercholesterolemia
EUCTR2017-001903-60-DESanofi-aventis recherche & développement500
进行中(未招募)
1 期
A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Risperidone Long-Acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar I Disorder, with Open-Label ExtensioBIPOLAR MANIA
EUCTR2004-003781-14-ESJohnson and Johnson Pharmaceutical Research and Development, una división de Janssen-Cilag, S.A
进行中(未招募)
1 期
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)Extensive Stage Small Cell Lung Cancer (ED SCLC)
EUCTR2016-003503-64-GBAbbvie Deutschland GmbH & Co. KG748
进行中(未招募)
不适用
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT 126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase InhibitorsMedDRA version: 15.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Alzheimer's Disease
EUCTR2011-004849-40-DEAbbVie Deutschland GmbH & Co. KG420